MedPath

Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

Not Applicable
Terminated
Conditions
Prostate Cancer
Registration Number
NCT03180398
Lead Sponsor
Henry Ford Health System
Brief Summary

This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.

Detailed Description

The study aims to generate intraprostatic lesions maps based on imaging, perform the treatment planning to compute the highest feasible simultaneous boosting dose to intraprostatic lesion and characterize longitudinal changes in imaging characteristics.

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
9
Inclusion Criteria
  • Histologically confirmed prostate adenocarcinoma
Exclusion Criteria
  • Patients with metal fragments or implanted devices such as pacemakers and aneurysm clips are not eligible for the study considering

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Detection of Imaging Biomarkers to Localize the Intraprostatic Lesions and Predict Radiation Treatment Response2 years

Identify the radiomics features selected from multimodal MRI to distinguish the dominant lesions from the normal tissues within the prostate. Track the changes of these features with longitudinal MRI scans to identify its correlation with the local control.

Tumor Response2 years

Tumor response as measured by an increase in PSA.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Henry Ford Health System
🇺🇸Detroit, Michigan, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.